{"disease":{"id":"infection-human-immunodeficiency-virus","name":"infection human immunodeficiency virus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06368453","title":"A Study to Evaluate the Performance, Usability, and Result Interpretation of INSTI® HIV Self-Test","phase":"NA","overall_status":"COMPLETED","enrollment_count":1728,"lead_sponsor_name":"bioLytical Laboratories","has_results":false},{"nct_id":"NCT00453440","title":"Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701","phase":"","overall_status":"COMPLETED","enrollment_count":1502,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT00441688","title":"Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":974,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01263015","title":"A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":844,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01227824","title":"A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":828,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01231516","title":"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831764","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":722,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02831673","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":719,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01205243","title":"ZIAGEN® Post-marketing Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02951052","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":618,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT03310515","title":"Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men","phase":"","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01910402","title":"A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01449929","title":"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT07209917","title":"Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"University of California, Irvine","has_results":false},{"nct_id":"NCT02076386","title":"A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01939197","title":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02576119","title":"A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT00094523","title":"Fosamprenavir Versus Other Protease Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02120352","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":309,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT04768517","title":"HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT01384734","title":"HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT01641809","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT06915779","title":"Long Term Follow-up of HPV Vaccine in HIV (CTN 236)","phase":"","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT00046176","title":"A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03369327","title":"Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":232,"lead_sponsor_name":"Tehran University of Medical Sciences","has_results":false},{"nct_id":"NCT03250910","title":"Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02415595","title":"Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT00951015","title":"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT07476339","title":"REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"CAN Community Health","has_results":false},{"nct_id":"NCT03922269","title":"Trans People Living With HIV Throughout Europe","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Chelsea and Westminster NHS Foundation Trust","has_results":false},{"nct_id":"NCT01536873","title":"Dolutegravir Expanded Access Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT04089488","title":"Incidence and Prevalence of Cancer in People Living With HIV/AIDS at Cancer Centers in Latin America","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":true},{"nct_id":"NCT00044577","title":"New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":166,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03078556","title":"Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02738138","title":"A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02266108","title":"Economic and Social Empowerment To Increase Upwards Mobility Among Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"University of California, San Diego","has_results":true},{"nct_id":"NCT02076178","title":"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT07061912","title":"A Study to Evaluate the Performance of INSTI® HIV Self Test When Performed by Unobserved Intended Users in the US","phase":"NA","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"bioLytical Laboratories","has_results":false},{"nct_id":"NCT02741557","title":"Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT02178592","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02480894","title":"A Open-label, Drug-Drug Interaction With Maraviroc (DDI)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT01803074","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02138084","title":"Drug-drug Interaction (DDI) Rifabutin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT03729778","title":"Impact of HIV-1 and Aging on Mucosal Vaccine Responses","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"VA Eastern Colorado Health Care System","has_results":false},{"nct_id":"NCT02479698","title":"Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03231943","title":"GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05065905","title":"Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"SPP Pharmaclon Ltd.","has_results":true},{"nct_id":"NCT02666053","title":"A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"ViiV Healthcare","has_results":false},{"nct_id":"NCT00071760","title":"Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT02467335","title":"Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"ViiV Healthcare","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}